Lotus Pharmaceutical Co., Ltd.
1795.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$47.44B
Close$
Share Statistics
| Market cap | $47.44 Billion |
|---|---|
| Enterprise Value | $99.70 Billion |
| Dividend Yield | $2.57 (1.42%) |
| Earnings per Share | $18.14 |
| Beta | 0.38 |
| Outstanding Shares | 260,000,999 |
Return
| Return on Equity | 15.49% |
|---|---|
| Return on Assets | 3.47% |
| Return on Invested Capital | 8.07% |
Valuation & Multiples
| P/E Ratio | 12.49 |
|---|---|
| PEG | -105.77 |
| Price to Sales | 1.66 |
| Price to Book Ratio | 1.94 |
| Enterprise Value to Revenue | 3.5 |
| Enterprise Value to EBIT | 13.56 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.59 |
| Debt to Equity | 2.41 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$3.42
Average shareholder expectationRevenue Estimate
$8.85 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$4.13
Average shareholder expectationRevenue Estimate
$8.98 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lotus Pharmaceutical Co., Ltd.
1,099 employees
CEO: Petar Antonov Vazharov Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and ...